+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Next Generation Biological Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

  • ID: 5438585
  • Report
  • August 2021
  • Region: Global
  • 100 pages
  • Infinium Global Research

The report on the global next generation biological drugs market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global next generation biological drugs market to grow with a CAGR of 20% over the forecast period from 2021-2027. The study on next generation biological drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on next generation biological drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global next generation biological drugs market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global next generation biological drugs market over the period of 2019 to 2027. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • High prevalence of cancer worldwide 
  • Ongoing clinical trial is being conducted by many pharmaceuticals companies 

2) Restraints

  • High cost involved in research and development for developing next-generation biologics 

3) Opportunities

  • Strategic alliance between the companies to make available next-generation biologics worldwide

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include;

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research;

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include;

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global next generation biological drugs market is segmented on the basis of therapies, and end users.

The Global Next Generation Biological Drugs Market by Therapies

  • Regenerative Medicine
  • Recombinant Coagulation Factors
  • Antibodies
  • Insulin Products

The Global Next Generation Biological Drugs Market by End Users

  • Hospitals
  • Specialty Clinics
  • Biotechnology Companies
  • Others

Company Profiles

The companies covered in the report include

  • F. Hoffmann-La Roche Ltd
  • Kyowa Kirin Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca
  • Seattle Genetics, Inc
  • ImmunoGen, Inc
  • Zumutor Biologics INC
  • Pfizer Inc
  • Xencor
  • Bayer AG

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the next generation biological drugs market.
2. Complete coverage of all the segments in the next generation biological drugs market to analyze the trends, developments in the global market and forecast of market size up to 2027.
3. Comprehensive analysis of the companies operating in the global next generation biological drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Note: Product cover images may vary from those shown
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Next Generation Biological Drugs Market Highlights
2.2. Next Generation Biological Drugs Market Projection
2.3. Next Generation Biological Drugs Market Regional Highlights

3. Global Next Generation Biological Drugs Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Next Generation Biological Drugs Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Therapies
3.5.2. Growth Matrix Analysis by End Users
3.5.3. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Next Generation Biological Drugs Market

4. Next Generation Biological Drugs Market Macro Indicator Analysis

5. Global Next Generation Biological Drugs Market by Therapies
5.1. Regenerative Medicine
5.2. Recombinant Coagulation Factors
5.3. Antibodies
5.4. Insulin Products

6. Global Next Generation Biological Drugs Market by End Users
6.1. Hospitals
6.2. Specialty Clinics
6.3. Biotechnology Companies
6.4. Others

7. Global Next Generation Biological Drugs Market by Region 2021-2027
7.1. North America 
7.1.1. North America Next Generation Biological Drugs Market by Therapies
7.1.2. North America Next Generation Biological Drugs Market by End Users
7.1.3. North America Next Generation Biological Drugs Market by Country
7.2. Europe 
7.2.1. Europe Next Generation Biological Drugs Market by Therapies
7.2.2. Europe Next Generation Biological Drugs Market by End Users
7.2.3. Europe Next Generation Biological Drugs Market by Country
7.3. Asia-Pacific 
7.3.1. Asia-Pacific Next Generation Biological Drugs Market by Therapies
7.3.2. Asia-Pacific Next Generation Biological Drugs Market by End Users
7.3.3. Asia-Pacific Next Generation Biological Drugs Market by Country
7.4. RoW 
7.4.1. RoW Next Generation Biological Drugs Market by Therapies
7.4.2. RoW Next Generation Biological Drugs Market by End Users
7.4.3. RoW Next Generation Biological Drugs Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Next Generation Biological Drugs Market
8.2. Companies Profiled
8.2.1. F. Hoffmann-La Roche Ltd
8.2.2. Kyowa Kirin Co., Ltd
8.2.3. Takeda Pharmaceutical Company Limited
8.2.4. AstraZeneca
8.2.5. Seattle Genetics, Inc
8.2.6. ImmunoGen, Inc
8.2.7. Zumutor Biologics INC
8.2.8. Pfizer Inc
8.2.9. Xencor
8.2.10. Bayer AG
Note: Product cover images may vary from those shown
Adroll
adroll